Literature DB >> 10229292

Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study.

F Collado-Mesa1, H M Colhoun, L K Stevens, J Boavida, J B Ferriss, B Karamanos, P Kempler, G Michel, G Roglic, J H Fuller.   

Abstract

AIM: To examine the prevalence of hypertension and the rates of hypertension awareness by investigating treatment and control among respondents to the EURODIAB IDDM Complications Study, and to explore the variation in hypertension management by age, sex and end-organ damage.
METHODS: A cross-sectional study, examining 3250 randomly selected Type 1 diabetic patients from 31 diabetes clinics in 16 European countries between 1989 and 1990. Mean age was 32.7 years (SD= 10.0) and mean duration of diabetes mellitus (DM) was 14.7 years (SD=9.3). Subjects were asked about a history of high blood pressure (BP) and current prescribed medications were recorded by the subject's physician. Hypertension was defined as having a systolic BP > or = 140 mmHg or diastolic BP > or = 90 mmHg or current use of antihypertensives. Control was defined as a BP < 130/85 mmHg.
RESULTS: Twenty-four per cent of subjects had hypertension, among whom fewer than one-half (48.5%) were aware of a previous diagnosis and a similar proportion (42.2%) were on treatment. Only 11.3% of those with hypertension were both treated and controlled. The majority (81%) of those receiving drug therapy for hypertension were on a single drug, most commonly an angiotensin-converting enzyme inhibitor (47%).
CONCLUSION: These data show the extent of undermanagement of hypertension in Type 1 DM across Europe prior to the publication of the St. Vincent Declaration and provide a useful baseline against which future improvements in the management of hypertension can be monitored.

Entities:  

Mesh:

Year:  1999        PMID: 10229292     DOI: 10.1046/j.1464-5491.1999.00007.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  12 in total

Review 1.  Cardiovascular disease risk in young people with type 1 diabetes.

Authors:  Janet K Snell-Bergeon; Kristen Nadeau
Journal:  J Cardiovasc Transl Res       Date:  2012-04-12       Impact factor: 4.132

2.  Trends in hypertension management in Type I diabetes across Europe, 1989/1990 - 1997/1999.

Authors:  S S Soedamah-Muthu; H M Colhoun; H Abrahamian; N N Chan; R Mangili; G P Reboldi; J H Fuller
Journal:  Diabetologia       Date:  2002-09-07       Impact factor: 10.122

Review 3.  Blood pressure control--effects on diabetic nephropathy progression: how low does blood pressure have to be?

Authors:  Christopher A Newton; Philip Raskin
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

4.  Association between the dietary approaches to hypertension diet and hypertension in youth with diabetes mellitus.

Authors:  Anke L B Günther; Angela D Liese; Ronny A Bell; Dana Dabelea; Jean M Lawrence; Beatriz L Rodriguez; Debra A Standiford; Elizabeth J Mayer-Davis
Journal:  Hypertension       Date:  2008-11-24       Impact factor: 10.190

Review 5.  Insulin resistance and hyperglycaemia in cardiovascular disease development.

Authors:  Markku Laakso; Johanna Kuusisto
Journal:  Nat Rev Endocrinol       Date:  2014-03-25       Impact factor: 43.330

Review 6.  Is the risk and nature of CVD the same in type 1 and type 2 diabetes?

Authors:  Lindsey Duca; Rachel Sippl; Janet K Snell-Bergeon
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

Review 7.  Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.

Authors:  Sarah D de Ferranti; Ian H de Boer; Vivian Fonseca; Caroline S Fox; Sherita Hill Golden; Carl J Lavie; Sheela N Magge; Nikolaus Marx; Darren K McGuire; Trevor J Orchard; Bernard Zinman; Robert H Eckel
Journal:  Diabetes Care       Date:  2014-08-11       Impact factor: 19.112

8.  Prevalence, awareness, and treatment of hypertension in patients with type 1 diabetes: a nationwide multicenter study in Brazil.

Authors:  Marilia B Gomes; Lucianne Righeti Monteiro Tannus; Alessandra Saldanha de Mattos Matheus; Roberta Arnoldi Cobas; Catia C Sousa Palma; Aline Tiemi Kano Silva; Carlos Antonio Negrato; Sergio Atala Dib; Melanie Rodacki; João Soares Felício; Luis Henrique Canani
Journal:  Int J Hypertens       Date:  2013-03-04       Impact factor: 2.420

Review 9.  An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK.

Authors:  C Pratoomsoot; H T Smith; A Kalsekar; K S Boye; J Arellano; W J Valentine
Journal:  Diabet Med       Date:  2009-08       Impact factor: 4.359

Review 10.  Cardiovascular disease in diabetes, beyond glucose.

Authors:  Robert H Eckel; Karin E Bornfeldt; Ira J Goldberg
Journal:  Cell Metab       Date:  2021-07-21       Impact factor: 31.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.